Crism Therapeutics Corp
CRTX
Company Profile
Business description
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Contact
Kingston Chambers
P.O. Box 173
Tortola
Road Town
VGBSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.60 | 9.70 | -0.11% |
| CAC 40 | 8,039.02 | 35.21 | -0.44% |
| DAX 40 | 24,001.25 | 48.49 | -0.20% |
| Dow JONES (US) | 47,311.00 | 225.76 | 0.48% |
| FTSE 100 | 9,755.72 | 21.36 | -0.22% |
| HKSE | 26,485.90 | 550.49 | 2.12% |
| NASDAQ | 23,499.80 | 151.16 | 0.65% |
| Nikkei 225 | 50,883.68 | 671.41 | 1.34% |
| NZX 50 Index | 13,576.81 | 44.17 | -0.32% |
| S&P 500 | 6,796.29 | 24.74 | 0.37% |
| S&P/ASX 200 | 8,828.30 | 8.50 | -0.10% |
| SSE Composite Index | 4,007.76 | 38.51 | 0.97% |